AN EXAMPLE OF APPLICATION OF THE POPULATION APPROACH TO TOXICOLOGICAL STUDIES F. Fiorentini 1, M. Simeoni 2, I. Poggesi 1, G. Westerberg 1, M. Rocchetti.

Slides:



Advertisements
Similar presentations
Karunya Kandimalla, Ph.D
Advertisements

PHARMACOKINETIC.
AbstractSchema Conclusion Pharmacokinetic profile of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous.
SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS
Response Optimization in Oncology In Vivo Studies: a Multiobjective Modeling Approach Maksim Pashkevich, PhD (Early Phase Oncology Statistics) Joint work.
Regression Analysis Once a linear relationship is defined, the independent variable can be used to forecast the dependent variable. Y ^ = bo + bX bo is.
Address for contact: FT Musuamba - Department of Clinical Biochemistry, Department of Pharmacokinetics, Metabolism, and Toxicology Av Hippocrate 10, B-1200.
Verify or refute the use of Non Linear Mixed Effect Model for Interferon effect on HCV Hila David Shimrit Vashdi Project Advisors: Prof. Avidan Neumann.
Title, in bold style Subtitle, in regular Max 3 lines of text totally NB! The graphic outside the slide will not show in “Slide Show” or on print WntResearch.
Pharmacokinetics of Drug Absorption
Two-compartment model
Pharmacokinetics & Pharmacodynamics of Controlled Release Systems Presented By: Govardhan.P Dept. of pharmaceutics, University College of Pharmaceutical.
One-compartment open model: Intravenous bolus administration
Nieves Velez de Mendizabal 1, 2, Kimberley Jackson 3, Brian Eastwood 4, Steven Swanson 5, David M. Bender 5, Stephen Lowe 6, Robert R. Bies 1, 2 A Population.
Laplace transformation
Chapter 13: Inference in Regression
Week 4 - Biopharmaceutics and Pharmacokinetics
Toxicokinetic Calculations
1 Clinical PK Optimal design and QT-prolongation detection in oncology studies Sylvain Fouliard & Marylore Chenel Department of clinical PK, Institut de.
Gokaraju Rangaraju College of Pharmacy
Exploratory IND Studies
Adding Safety Pharm Endopoints To General Tox Studies - II Michael J Engwall, DVM, PhD Principal Scientist Safety and Exploratory Pharmacology Toxicology.
University of Jordan-Faculty of Pharmacy
Results: In the presence of PD measurements, PK data provided little additional information. By a limited PD sampling the number of patients on target.
1 Data Analysis © 2005 Germaine G Cornelissen-Guillaume. Copying and distribution of this document is permitted in any medium, provided this notice is.
1 I4E-MC-JXBA and JXBB Phase 2 Study to Evaluate the PK and Drug-Drug Interaction of Cetuximab and Cisplatin (JXBA) Cetuximab and Cisplatin (JXBB)
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 3: Incomplete Data in Longitudinal Studies.
Dynamic Lines. Dynamic analysis n Health of people and activity of medical establishments change in time. n Studying of dynamics of the phenomena is very.
Yaomin Jin Design of Experiments Morris Method.
Background Objectives Data Simulation in human Conclusion -F14512, a polyamine-vectorized anti-cancer drug which combines an epipodophyllotoxin core targeting.
In rodent studies, microsampling provides an opportunity to sample main study animals for toxicokinetic (TK) assessment rather than using satellite animals.
Introduction to PK/PD Modeling for Statisticians Part 1
Population Pharmacokinetic Characteristics of Levosulpiride and Terbinafine in Healthy Male Korean Volunteers Yong-Bok Lee College of Pharmacy and Institute.
1-Compartment Oral Dosing 400 mg of moxifloxacin is administered orally to Mr BB, a 68 yr old male who weighs 75 kg. Blood samples were drawn following.
Area under the plasma concentration time curve. IMPORTANCE OF AUC Pharmacokinetics - measurement of bioavaibility absolute, relative Biopharmaceutics.
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
Relative Values. Statistical Terms n Mean:  the average of the data  sensitive to outlying data n Median:  the middle of the data  not sensitive to.
Multiple dosing: intravenous bolus administration
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Noncompartmental Models. Introduction The noncompartmental approach for data analysis does not require any specific compartmental model for the system.
1 METHODS FOR DETERMINING SIMILARITY OF EXPOSURE-RESPONSE BETWEEN PEDIATRIC AND ADULT POPULATIONS Stella G. Machado, Ph.D. Quantitative Methods and Research.
Continuous intravenous infusion (one-compartment model)
Model-based dose selection for next dose- finding trial 1. Introduction Exploratory clinical development trials often include biomarkers or clinical readout.
BIOPHARMACEUTICS.
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
Pharmacokinetics of Drug Absorption Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Learning Objectives After this section, you should be able to: The Practice of Statistics, 5 th Edition1 DESCRIBE the shape, center, and spread of the.
1.Andersson, T, et al. Clin Pharmacokinet 2001;40: Hassan-Alin, M, et al. Eur J Clin Pharmacol 2000;56: Population Pharmacokinetic Modelling.
1. Objectives Novartis is developing a new triple fixed-dose combination product. As part of the clinical pharmacology program, pharmacokinetic (PK) drug-drug.
1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.
Objectives Compartment Modeling of Drugs Models describing drug concentration-time profiles Multi-compartment Models.
415 PHT Plasma Level – Time Curve
1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
The process of drug development. Drug development 0,8 – 1 mld. USD.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
MULTIPLE DOSAGE REGIMEN
Lung Cancer Cell Line Nº StudiesStrainNº Mice H44113Athymic nude119 A5492CB-17scid15 Calu-62CD-1 nu/nu25 H16501Athymic nude8 H19751Athymic nude8 H21226Athymic.
Drug Response Relationships
Simulation setup Model parameters for simulations were tuned using repeated measurement data from multiple in-house completed studies and baseline data.
MECH 373 Instrumentation and Measurements
The Stages of a Clinical Trial
Applications of Pharmacokinetics
Biopharmaceutics Dr Mohammad Issa Saleh.
ANALYSIS OF POPULATION KINETIC DATA
Predictive Performance of a Myelosuppression Model for Dose Individualization; Impact of Type and Amount of Information Provided Johan E. Wallin, Lena.
Hawler Medical University
Two Halves to Statistics
I can determine the different sampling techniques used in real life.
Presentation transcript:

AN EXAMPLE OF APPLICATION OF THE POPULATION APPROACH TO TOXICOLOGICAL STUDIES F. Fiorentini 1, M. Simeoni 2, I. Poggesi 1, G. Westerberg 1, M. Rocchetti 1 1 Nerviano Medical Science, Nerviano, Italy, 2 University of Pavia, Pavia, Italy Abstract Usually, pharmacokinetic information is obtained from satellite groups of animals during toxicological studies. This approach provides a characterization of the toxicological findings only in relation to the average estimates of the systemic exposure (typically C max, t max, AUCs) in the satellite groups. In this way, the individual toxicological observations remain difficult to interpret in absence of a direct comparison with the exposure of the main study animals. A sparse sampling design together with a population analysis could however allow merging the individual toxicological observations with the corresponding estimate of the systemic exposure in the same animal. This allows a considerable expansion of the degree of information obtainable from the toxico-pharmacokinetic profile of the compound and, in addition, could provide reduction of costs in the subsequent phases of development. An example of a real application of this kind of approach is provided here. Three typical studies that constitutes part of a toxicological program of a new intravenous anticancer drug were considered: an acute study after single administration, a short term study (7 days repeated administration) and a cyclic dose study. The data were analysed by using a 2-compartment model with elimination from the central compartment and a proportional residual error. The results compared with those obtained with more traditional approaches confirmed the added value of the population analysis. Introduction The approach and the model Working scheme: 1. Analysis of study 1 (extensive sampling) for establishing the PK model. 2. Two-stages approach to obtain initial estimates of the subject-specific parameters. 3. Simultaneous analysis of studies 1 and 2 using a ‘population approach’ (analyeses carried out with WinNonMix version and NONMEM version V). 4. Comparison with the parameters obtained using the non-compartmantal analysis (NCA) from the average plasma concentration-time data Method of analysis: - 2-compartment open model with firts order elimination. - Exponential terms for describing subject-specific random effects. - Proportional residual error. - First-order linearization. Anticancer drug, IV bolus administration Tox program in rats Study 1 7-day repeated dose at 2.5, 5.0 and 10 mg/kg/day. Extensive sampling: 3 mouse/dose. Blood sampling at: pre-dose, 5 min, 0.5,1,3, 6 and 24h after 1 st and 7 th administration. Limited sampling performed on the main toxicological groups of animal. 8 rats/dose, 1 sampling time per animal distributed between the following: 5 min, 0.5, 1, 3, 6 and 24h after 1 st and 7 th administration. Study 2 Three cycles of 3-day treatment separated by 5-day interval. Doses: 2.5, 5 and 10 mg/kg/day. Limited sampling on main toxicological groups. 12 rats/dose, 1 sampling time/animal/cycle of treatment distributed at the following time points: 5 min, 0.5, 1, 3, 6 and 24h. The data During the pharmacotoxicological evaluation of a drug, the information on the exposure of a drug is often obtained from ‘satellite groups’ of animals. Due to this, the characterization of the toxicological findings is provided only in relation to the average estimates of the systemic exposure (typically C max, t max, AUCs). In this way, however, the individual toxicological observations remain difficult to be interpreted due to the absence of a direct estimation of the exposure achieved in the individual animals. Sparse sampling techniques together with population pharmacokinetic analysis is able to merge the individual toxicological observations with the relevant estimates of the systemic exposure in the same animal, thereby allowing a smarter use of the information obtained from the toxico-pharmacokinetic profile of the compound 1. In addition, using this approach, costs can be reduced in the subsequent phases of drug development when long term toxicity studies are needed. Study 1-limited sampling Study 2 Conclusions Winnonmix provided results in good agreement with NONMEM analysis Overall, there was an excellent agreement between the pharmacokinetic parameters obtained using the population approach and the non-compartmental analysis. The population approach allowed analysing studies with a repeated schedule of treatment with only 2 or 3 sampling times per animal and consequent reduction of disturbance. In addition, it was made possible the correlation of the individual PK profiles with the corresponding toxicological findings elicited by the different schedule of treatment. Finally, the possibility of using a limited sampling strategy allowed to plan additional long term studies with a substantial reduction of the cost/time of bioanalysis. Overall, the use of population approaches confirmed to be useful also in preclinical development. 1 Poggesi I, Simeoni M. Population pharmacokinetics in preclinical development. An application to toxicokinetics. First Italian symposiumon population Pharmacokinetics. Turin, March 19, Study1-extensive sampling Results PAGE Uppsala,17-18 June 2004